Immungenetics Overview

  • Founded
  • 2009
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 1

Immungenetics General Information


Developer of drugs intended to treat neurodegenerative and auto-immune diseases. The company's drugs treat inflammation, aging, mitochondrial dysfunction, Alzheimer's, dementia or memory disorders, enabling doctors to select a personalized medication for their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • Deutsche-Med-Platz 1
  • 18057 Rostock
  • Germany
+49 0172 0000000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immungenetics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Jan-2013 Completed Generating Revenue
To view Immungenetics’s complete valuation and funding history, request access »

Immungenetics Executive Team (6)

Name Title Board Seat Contact Info
Jonas Fischer Co-Chief Executive Officer
Max Brattig Co-Chief Executive Officer
Jens Pahnke Co-Founder & Lead Researcher
Saleh Ibrahim Co-Founder & Lead Researcher
Guido Hillebrands Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Immungenetics Board Members (3)

Name Representing Role Since
Guido Hillebrands Self Chairman 000 0000
Peter Heydebreck Self Board Member 000 0000
Tilman Fischer Immungenetics Board Member 000 0000
To view Immungenetics’s complete board members history, request access »

Immungenetics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innoveas Venture Capital Minority 000 0000 000000 0
To view Immungenetics’s complete investors history, request access »